Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:32 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 6,268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid Clear all
Completed Phase 3 Interventional Results available

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

NCT00699153
View directory record Official record
Conditions
Ocular Inflammation
Interventions
Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Nov 1, 2026, 6:32 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Bullhead City, Arizona • Los Angeles, California • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

NCT00003783
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Nov 1, 2026, 6:32 PM EST
Recruiting Phase 3 Interventional

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

NCT06996951
View directory record Official record
Conditions
Cystic Fibrosis (CF), Chronic Rhinosinusitis (CRS)
Interventions
STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID, CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
Other · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00729586
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
108
States / cities
Burbank, California • Palo Alto, California • San Diego, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 4 Interventional Results available

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

NCT02340169
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topicort® (desoximetasone) Topical Spray, 0.25%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Nov 1, 2026, 6:32 PM EST
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 1, 2026, 6:32 PM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 1 Interventional

Trial of Combination Therapy to Treat COVID-19 Infection

NCT04482686
View directory record Official record
Conditions
COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions
Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 1, 2026, 6:32 PM EST
Active, not recruiting Phase 2 Interventional

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973
View directory record Official record
Conditions
Amyloidosis
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 6:32 PM EST
Recruiting Phase 2 Interventional

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

NCT06841705
View directory record Official record
Conditions
Immune Checkpoint Inhibitor-Related Colitis
Interventions
Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
Drug · Other
Lead sponsor
Shilpa Grover, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 2 Interventional

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

NCT00083005
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Nov 1, 2026, 6:32 PM EST
Withdrawn Phase 1 Interventional

A Clinical Trial of Patients With Melanoma

NCT02915666
View directory record Official record
Conditions
Melanoma
Interventions
Digoxin Combination, Dabrafenib, Trametinib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 2 Interventional Results available

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00376961
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
147
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

NCT01103622
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Digoxin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
Satraplatin, Prednisone
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
105
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 1, 2026, 6:32 PM EST
Completed Not applicable Interventional Results available

Smart Telehealth Exercise Intervention to Reduce COPD Readmissions

NCT03089853
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Nov 1, 2026, 6:32 PM EST
Terminated Phase 1 Interventional

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

NCT00044837
View directory record Official record
Conditions
HIV Infections
Interventions
Medroxyprogesterone acetate, Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Nov 1, 2026, 6:32 PM EST
Recruiting Not applicable Interventional

Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)

NCT04355572
View directory record Official record
Conditions
Polycystic Ovarian Syndrome in Adolescent Females, Vitamin D Deficiency
Interventions
Vitamin D 4000IU daily, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 4 Interventional Results available

Long-acting Beta Agonist Step Down Study

NCT01437995
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone/Salmeterol Diskus, Fluticasone Diskus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 4 Interventional

Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

NCT00560586
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Budesonide, placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 12 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 1, 2026, 6:32 PM EST
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Nov 1, 2026, 6:32 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment Study of Vitamin D Deficiency in Adolescents

NCT01784029
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D3
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
13 Years to 20 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 1, 2026, 6:32 PM EST